Messaging Toolkits
Monitor Payer Messaging Perception: Breast...
In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in breast cancer.
In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in breast cancer.
In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in non-small cell lung cancer.
In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in oncology biosimilars.
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.
Learn how a product’s placement on pathways affects its utilization and uptake, and ultimately, patient’s access to life saving therapies.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
Description